Neuro-Oncology

ISSN: 1522-8517

Journal Home

Journal Guideline

Neuro-Oncology Q1 Unclaimed

Oxford University Press United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Neuro-Oncology is a journal indexed in SJR in Oncology and Cancer Research with an H index of 125. It has an SJR impact factor of 4,005 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 4,005.

Neuro-Oncology focuses its scope in these topics and keywords: glioblastoma, glioma, tumor, cell, central, diagnosis, therapeutic, leukocyte, nervous, tumors, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

3465 €

Non OA

Metrics

Neuro-Oncology

4,005

SJR Impact factor

125

H Index

251

Total Docs (Last Year)

611

Total Docs (3 years)

7551

Total Refs

4934

Total Cites (3 years)

453

Citable Docs (3 years)

7,14

Cites/Doc (2 years)

30,08

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


glioblastoma, glioma, tumor, cell, central, diagnosis, therapeutic, leukocyte, nervous, tumors, system, cells, brain, disease, dna, clinical, egfrdescriptive, classics, cancers, cancersmicrornas, care, casecontrol, cdactivated, cerebrospinal, chartsa, clarity,



Best articles by citations

Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma

View more

Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis

View more

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab

View more

Response and progression in recurrent malignant glioma

View more

Consensus Conference on Cancer Registration of Brain and Central Nervous

View more

Editorial

View more

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

View more

DRES-07. SIGNIFICANT SEX DIFFERENCES IN TEMOZOLOMIDE EFFICACY IN GLIOBLASTOMA (GBM) ARE DETECTABLE IN CELL AND PATIENT BASED EVALUATIONS

View more

Medical management of brain tumors and the sequelae of treatment

View more

Incidence of brain metastasis at initial presentation of lung cancer

View more

Biology and management of ependymomas

View more

CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2

View more
SHOW MORE ARTICLES

Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life

View more

Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models

View more

Surgery for primary supratentorial brain tumors in the United States,

View more

Immunohistochemical staining for ganglioside GD1b as a diagnostic and prognostic marker for primary human brain tumors

View more

Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients

View more

Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine

View more

Penetration of intra-arterially administered vincristine in experimental

View more

Atypical white matter volume development in children following

View more

ATPS-74IS MORE CHEMOTHERAPY BETTER? PROLONGED SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA RECEIVING MORE THAN SIX CYCLES OF ADJUVANT TEMOZOLOMIDE

View more

Posttransplant primary CNS lymphoma

View more

Retraction notice: Diffuse midline glioma with H3 K27M mutation: a comparison integrating the clinical, radiological, and molecular features between adult and pediatric patients

View more

AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor

View more

FAQS